



AYURVEDIC MANAGEMENT OF PLEURAL EFFUSION W.S.R TO URA :STOYA - A CASE REPORT

Ayurveda

**Shivaprasad
Sharma
Thanugula***

Clinical Research Officer, Department of MCH, Transitional Health Science & Technology Institute, Autonomous Body Of Ministry Of Science, Ncr Biotech Science Cluster, 3rd Milestone, faridabad – Gurugram, Haryana, India *Corresponding Author

**Kirankumar V
Mutnali**

Principal & Professor, Department of Kayachikitsa, KLE Ayurveda Medical college, Chikodi, Karnataka, India

ABSTRACT

Pleural cavity is filled with minimal amount of fluid sufficient enough to facilitate the free expansion of the lungs. Pleural effusion is a condition where excess of fluid gets accumulates within the pleural cavity resulting in breathlessness, pleuritic chest pain and dry cough. The precise description of this condition although available in later period lexicons of Ayurveda, the above presentation of clinical features is found in multiple conditions like Shwasa (Dyspnea), Parshwashoola (Flank pain), Kasa (Cough), Sosha (Pulmonary Tuberculosis) etc. Bhaishajya Ratnavali, reports the condition named Urahstoya which exactly correlates to pleural effusion. Here, describe a female case of 58 years diagnosed with Urahstoya (pleural effusion) managed by a Shodhana (detoxification) procedure called Nitya Virechana (Gut cleansing daily). Simultaneously patient was subjected to Vatanulomana (facilitating movement of Vata Dosha in its natural direction), Kapha pacifying, Mutrala (diuresis), Vishaghna (antidote) and Jwaraghna (antipyretic) medicaments. The patient showed steady improvement over five months of active treatment i.e., from 9th April to 31st August 2018, which was consistent and complete with no relapse during follow up till 11th January 2019.

KEYWORDS

Pleural effusion, Urahstoya, Shwasa, Shodhana, Nitya Virechana

INTRODUCTION

The anatomical architecture of human lung provides minimal amount of free fluid in the pleural space i.e., 10 to 20 ml, which helps in smooth expansion of lungs to preventing friction. Excess fluid hinders lung expansion resulting in dyspnea, cough and pleuritic chest pain during breathing limiting the execution of routine activities. The accumulated fluid can be either transudative or exudative based on the underlying etiology. Intervention is therefore essential to eliminate the excess fluid and minimize the discomfort. Thoracocentesis is the mainstay of treatment in contemporary science and is quite effective as well. However, it comes with risks and complications. In *Ayurveda*, these symptoms are documented under the condition *Urahstoya*. The condition basically involves all three *Dosha* in its pathology with derangement in *Vata* and *Kapha* at initial phase. *Urahstoya* is characterized by excess accumulation of *Ambu* (serous fluid) in *Shleshmadhara Kala* (pleural cavity) of *Phupphusa* (lungs) one among *Koshthanga* (body cavities). *Ayurveda* recommends the treatment principles of *Mutrakrichra* (dysuria), *Hridroga* (cardiac ailments), *Shwasa* (breathing ailments), *Kasa* (cough), *Udara roga* (ascites) and *Shotha* (edema) in the management with medications possessing *Kapha Vata* pacifying and *Mutrala* (diuresis). Ayurvedic management promises good outcome without subjecting the patient to the risk of interventional procedures like thoracocentesis in uncomplicated cases.

Patient Information

A 58 year old female patient, non-diabetic but a known case of bronchial asthma since eight years and hypertension since one year approached to the PRANADA OPD of KLE Ayurveda Hospital on 9th April 2018 with chief complaints of breathlessness (ATS-Grade3), chest pain (VAS 6), dry cough (VAS 6) and coryza since last 8 days associated with pain in left shoulder radiating to left arm with tingling sensation, disturbed sleep and low backache. She has complained of inability to lie in supine position. The above complaints were insidious and gradually progressive in nature, aggravated by physical exertion and relieved by lying in left lateral position. On deep inspiration, the patient was experienced stabbing type of pain in the left side of the chest. There was associated generalized body weakness.

Clinical Findings & Diagnostic Assessment:

The general physical examination of the patient was within normal limits with the vitals viz., temperature, pulse and respiratory rate in normal range and the blood pressure was well controlled. Inspection of the chest showed reduced expansion on the left side and apex beat was not remarkable. On palpation the chest movements, tactile vocal fremitus were reduced. Percussion revealed stony dull-note and auscultation confirmed absence of air entry in left middle and lower

lung fields with no adventitious sounds. Details of examination findings at different time points have been summarized. The right lung and other systems were within the norm. A diagnosis of left sided pleural effusion was made based on the history and clinical examination.

Patient was followed up over 1st, 8th, 15th, 32nd, 39th, 50th, 60th, 95th, 119th and 144th day. She was called for first follow up on 8th day of intervention to ascertain the efficacy of treatment and consider referring to higher centre in case there was no relief. During follow-up when improvement was noted, she was called for second follow-up on 15th day. Assessment was based on history of Dyspnea (Grading of ATS), cough (VAS), chest pain (VAS) and concurrent clinical assessment of respiratory system. Radiological assessment was done prior and post completion of intervention.

Diagnosis: *Urahstoya* (left side pleural effusion involving the middle and lower lobes)

Timeline

Eight days prior to the onset of current symptoms, the patient had high grade fever, productive cough and ATS Grade 2 breathlessness. A provisional diagnosis of pneumonia was made by a local Homeopathic physician who advised **Tab Cefuroxime 250 MG** twice in a day and Montelukast sodium once daily after food, Tablet Pantozol-DSR one two times a day before food for five days. Owing to her incomplete relief she approached our hospital for further evaluation and management. The routine blood investigations revealed no derangement except that the Erythrocyte Sedimentation Rate was 70mm at the end of one hour and TLC was 11,600cells/mm³. Chest X-ray of the patient in PA view confirmed left sided moderate pleural effusion with underlying collapse/consolidation. From last eight years patient is using inhaler Beclomethasone and Salbutamol once daily. Patient is on Tablet Amlodipine Besylate and Atenolol 50mg once daily since one year for management of hypertension. The history and clinical examination is consistent with presentation of post-pneumonic pleural effusion. Case reporting is done as per CARE case report guidelines. (<http://www.care-statement.org>)

Therapeutic Intervention:

The approach towards management in this case was on the principles of *Udara Roga* and *Shwasa roga* wherein the herbs with property of diuresis, *Vatanulomana* (facilitating movement of *Vata Dosha* in its natural direction), *Kapha Vata* pacifying when given orally in the present case over a period of five months, the result was encouraging. The patient was treated with *Nitya Virechana* (NV), *Lepa*, *Shamana Aushadhi* (oral medications) with due consideration to her

Kaphapittala Prakruti (constitution) and *Kapha Vata Dosha* dominance in the pathogenesis of the pleural effusion (PE). Various timelines and details of treatment with chronological intervention, medicines used, dosage, duration and outcome have been mentioned in *Lepa* is a procedure in which herbs are made into fine powders and mixed homogenously in warm water to attain a fine paste. This warm paste was applied once daily to the left side of the chest, back and flank. The paste was kept for thirty minutes and washed off after drying with lukewarm water.

TABLE No. 1 PATHOGENESIS of URAHSTOYA)

S.No	Literature on Urahstoya	Literature on Pleural Effusion	Clinical Manifestation
1.	<i>Urahstoya</i> there is excess accumulation of <i>Ambu</i> (serous fluid) in <i>shleshmadhara kala</i> (pleural cavity) of <i>Phupphusa</i> (Lungs) which is one among <i>kosthanga</i> (body cavities) similar to the <i>Udara Roga</i> and <i>Shotha</i> .	Accumulation of excess fluid in pleural cavity hampering free alveolar expansion.	Preceded with pneumonia followed by pleural effusion suggesting <i>kapha</i> and <i>pitta</i> involvement.
2.	Parshwashoola and Shwasa develops when the <i>vata dosha</i> is occluded by <i>Kapha dosha</i> in the <i>parshwa</i> and <i>kukshi</i> areas producing <i>Adhmana</i> , borborygmi, pricking kind of pain, breathing difficulty. The pain in flanks can be correlated to pleuritic chest pain. Shwasa (Breathlessness) manifests because of inability of the lung to expand in the presence of serous fluid.	PE restricts the normal expansion of lung resulting in breathlessness, dry cough, pleuritic chest pain. Examination will reveal stony dull note on percussion, reduced vocal fremitus and resonance and absence of air entry. PE can be of two types, transudative and exudative. The most common cause of exudative type is pulmonary infection like pneumonia. Transudative effusion can occur in conditions causing hypoproteinemia or cardiac failure. Untreated and neglected cases land in respiratory failure, empyema and pleural adhesions. Radiological diagnosis x-ray chest is gold standard test. Ultrasonography however is more sensitive. Thoracocentesis is the treatment of choice.	Prior history suggestive of pneumonia 8 days back. Breathlessness grade 3, Pleuritic chest pain and Cough . Reduced chest expansion and vocal fremitus, stony dull on percussion , absent air entry, reduced vocal resonance.

Table No. 2 Details of Therapeutic Interventions At Different Timelines

S.No	Duration of Intervention	Lakshana	Samp rapti	Dosha vrudhi /kshaya avastha	Chikitsa (Shodhana & Shamana)
01	1 st to 32 nd day	Breathlessness Pleuritic chest pain Cough Coryza	Kapha vata	Kaphapitta samsrusta vatavrudhi	1.Nitya virechana with haritaki churna 5gm with warm water 7am 2.Lepa (Devadaru, Daruharidra, Haridra, Vacha, Triphala, Ashwagandha, Rasna)
02	1 st to 144 day	Breathlessness Pleuritic	Kapha vata	Kaphapitta samsrusta vatavrudhi	1.Tab. Lakshmi Vilasa Rasa (Naradeeya) [LVRN]

chest pain Cough	Kapha vata	Kaphapitta samsrusta vatavrudhi	2.Suvarnamalini Vasanta Rasa[SMVR], 3.Talisadi churna (TC) with Rasasindhura (RS), TC with sitopaladi churna(SPC)and RS, TC with 100 puti Abhraka bhasma and RS 4.Pushkaramruth(PA) 5.Madiphala rasayana(MR), 6.Panchamrutha parpati(PA), 7.Tab Dashamoola katutraya[DKK], 8.Shwasa Kutara Rasa [SKR], 9.Swamla Compound [SC].
---------------------	------------	---------------------------------	---

Table No. 3 TIMELINE -Details of Therapeutic Intervention

S.NO	VISIT	INTERVENTION	OBSERVATIONS
1	Visit 1 (09-04-2018) 1 st day	1.Tab.LVRN 1TID/AF 2.Tab.SMVR 1 BD AF 3. Syp. Pushkaramruth 4TSF QID AF 4.TC- 100 gms + RS -2.5 gms - 1 Tsf QID with Honey AF 5.Haritaki churna 10gm with warm water on empty stomach 6.Devadaru + Daruharidra + Haridra + Vacha + Triphla + Ashwagandha + Rasna churna ⁷ Lepa with warm water to left flank & back Twice Daily	Orthopnoea Cough bouts and intensity reduced Chest pain intensity reduced (?) Diminished Air entry in left lung in middle and lower lobe
2	Visit 2 (17-04-2018) 8 th day	1.Tab.LVR[N] 3 1TID/AF 2.Tab. SMVR 1 BD AF 3.Syp. Pushkaramruth5 4TSF QID AF 4.TC50gm + SPC 50 gm + RS - 2 gms 5.Haritaki churna 10gm with warm water on empty stomach 6.Devadaru + Daruharidra + Haridra + Vacha + Triphla + Ashwagandha + Rasna churna 7 Lepa with warm water to left flank & back Twice daily	Orthopnea Occasional Dry cough Exertional dyspnea Diminished Air entry in left lung in middle and lower lobe Loss of appetite
3	Visit3 (24-04-2018) 15 th day	Continued 1-6 medicines Added 1.Tab.Pravala Panchamrutha Ras [PAP] 1BD BF	Orthopnea subsided no dyspnea no chest discomfort Diminished Air entry in left lung in middle and lower lobe
4	Visit 4 (11-05-2018) 32 nd day	1.Madiphala rasayana [MR] 2tsf TIDBF 2. Swamla compound [SC] 1tsf BD AF 3.Pushkaramoolasa 3tsf BD	No chest pain Diminished Air entry in left lung at base Appetite improved
5	Visit 5 (18-05-2018) 39 th day	1. TC 50gm +100puti AB + RS - 2gms 1tsf QID with Honey AF 2.Tab .DMKK 1TID AF 3.Pushkaramrith 3 TSF TID AF 4.Tab. SMVR 1BD AF	Diminished Air entry in left lung at base
6	Visit 6 (29-05-2018) 50 th day	1.PUSHKARAMRITH 3tsf TID AF 2. Tab. DMKK 1TID AF 3. Tab. SMVR 1TID AF	Diminished Air entry in left lung at base
7	Visit 7	1.PUSHKARAMRITH 3tsf TID AF	Diminished Air entry in left lung at

	(08-06-2018) 60 th day	2. Tab. DMKK 1TID AF 3. Tab. SMVR 1TID AF	Diminished Air entry in left lung at base
8	Visit 8 (13-07-2018) 95 th day	1.PUSHKARAMRITH 3tsf TID AF 2. Tab. DMKK 1TID AF 3.Tab. SKR 1BD AF 4.SC 1Tsf BD	Air entry improved in left lung X ray chest shows 80% resolution of effusion
9	Visit 9 (06-08-2018) 119 th day	1.Tab. R G Forte 1BD AF 2.Tab. Biogest 1BD AF 3. PUSHKARAMRITH 3 TSF TID AF 4. Tab. SMVR 1TID AF	No complains pertaining to respiratory system
10	Visit 10 (31-08-2018) 144 th day	1. Tab .DMKK 1TID AF 2.Shwasa Kuthara Ras 1BD AF 3.TC 50gm+RS 2gm+100puti AB 1tsf AF 4. Flexy Liniment E/A	No complains pertaining to respiratory system

Follow-up & Outcome:

Patient was treated from April to December 2018. Active intervention for PE was administered till August 2018 (144 days). Follow-up of the patient was continued till her last visit in January 2019 for other complaints like *Sandhigata Vata* (osteoarthritis of knee joints) and *Gridhrasi* (sciatica).

The outcome on respiratory system findings like air entry on auscultation exhibited steady improvement over follow ups. Clinical assessment parameters like breathlessness, cough and chest pain exhibited gradual recovery from baseline score 3 (ATS), 6 (cough) and 6 (VAS) to 1(ATS), 2 (cough) and 4 (VAS) on 32nd day and near to complete recovery by 144 days. Orthopnoea subsided on 15th day. On 8th and 15th day visit patient complained of loss of appetite, heart burn, sour eructation and nausea. Accordingly diagnosis of *Urdhwaga Amlapitta* was done and was treated with *Tab Pravala Panchamrita* 1 twice a day and *Madiphala Rasayana* 3 teaspoonful twice a day before food. During this visit medications to improve *Agni* and alleviate *Ama* were added. ESR on 4 August 2018 was 16mm at the end of one hour and x ray chest show 80 % reduction in effusion. The effusion reduced completely on 4 December as evidenced by chest x-ray. Chronological improvement has been summed up in Table No. 4.

Table 4 Assessment of Symptoms and Signs during different followup

S.No	Date	Dyspnea (ATS grade)	Cough (VAS)	Chest pain (VAS)	Air entry in left lung (diminished in)	Orthopnoea (Present/Absent)	Anorexia (Present/Absent)	Generalized weakness
1	1 st day	3	6	6	Mild & lower lobe	Present	Absent	+++
2	8 th day	2	4	4	Mild & lower lobe	Present	Present	+++
3	15 th day	1	2	4	Mild & lower lobe	Absent	Present	+++
4	32 nd day	1	2	4	Lower lobe	Absent	Absent	++
5	39 th day	1	2	2	Lower lobe	Absent	Absent	++
6	50 th day	0	0	0	Lower lobe	Absent	Absent	+
7	60 th day	0	0	0	Lower lobe	Absent	Absent	+
8	95 th day	0	0	0	-	Absent	Absent	-
9	119 th day	0	0	0	-	Absent	Absent	-
10	144 th day	0	0	0	-	Absent	Absent	-

+ indicates severity of symptom, -indicates absence of sign or symptom

DISCUSSION:

Urahstoya is a *Pranavaha srotasa* (respiratory system) disease with dominance of *Vata* and *Kapha Dosha* where in there is fluid

accumulation within the pleural space. The condition develops as a result of vitiation of *Vata Dosha* exciting the *Pitta* and *Kapha Dosha* and further vitiating them. Thus vitiated *Vata-Pitta-Kapha Dosha* disturbs the *Rasa, Rakta Dhatu* producing *Shleshaka Kapha Dusti* in *Urah* (thoracic cavity) which is followed by the accumulation of the fluid in *Shleshmadhara Kala*. The patient under study had ATS Grade 3 breathlessness, chest pain of VAS 6 and cough of VAS score 6 before initiation of treatment. Ensuring that her life was not at stake, an individualized diligent treatment plan was made and initiated. Observations and findings were noted during regular follow-ups. Treatment was based on the principles of *Udara Roga* and *Shotha*. *Nitya Virechana* (Gut cleansing on daily basis), *Lepa* (topical application) with oral medications were administered for five months.

NV was administered with ten grams of *Haritaki* (*Terminalia chebula* Linn.) powder for 32 days on daily basis in order to achieve elimination of fluid by inducing bowel movement and the average number of *Vegas* attained were three. NV also acts as diuretic, rectifies the diminished appetite. Oral medications were targeted at normalizing *Vata, Kapha Dosha* and maintenance of digestion to prevent *Ama* formation.

At first visit patient was advised Tab. *Lakshmi Vilasa Rasa* (*Naradeeya*) [LVRN] one tablet twice a day post meal, Tab *Suvarnamalini Vasanta Rasa* [SMVR] one tablet twice a day post meal, Syrup *Pushkaramruth* 15 ml twice a day with 30ml warm water and combination of *Talisadi Churna* (TC) 100 gms and *Rasasindhooara* 2.5 gm in a dose of six gram thrice a day post meal.

LVRN is highly effective in cold, cough and dyspnea. Ingredients like *Krishna Abhraka Bhasma* (incinerated Mica), *Shuddha Gandhaka* (processed Sulphur), *Karpooara* (*Cinnamomum camphora*. (L.) J. Presl.), *Vridhdharu* (*Argyrea nervosa*. (Burm.f.) Bojer.), *Nagabala* (*Sida Veronicaefolia* Lam.), *Atibala Atibala* (*Abutilon indicum* (Linn.); act as *Rasayana*, antimicrobial and antipyretic. SMVR is a herbomineral formulation, indicated primarily in chronic fever, cough, asthma and tuberculosis. Ingredients like *Suvarna Bhasma*, *Mukta Bhasma*, *Kajjali*, *Ayas*, and *Tamra Bhasma* enhance immunity and are antimicrobial formulation. It balances *Vata & Kapha Dosha*. Symp. *Pushkaramruth* a proprietary medicine of Swadeshi Pharmaceuticals Pvt.Ltd is indicated in bronchial asthma, bronchitis, cough and cold. The ingredients *Pushkaramoola*, *Vasa*, *Trikatu*, *Yasthimadhu*, and *Bharangi* are potent bronchodilators, antispasmodic and decongestants. TC was administered to relieve cough, breathlessness and induce expectoration, enhance digestion and is *Moodha Vata Anulomana*. *Haritaki Churna* 5gm with warm water was administered to cleanse the accumulated *dosha* as a NV medicine. *Haritaki* is *Vata Anulomaka*; regulation of movement of *Vayu* cures *Shwasa & Kasa*.

During follow-ups when patient complained of generalized weakness, TC was added with *Shataputi Abhraka Bhasma* one gram and *Sitopaladi churna* in equal quantity and Swamla Compound a proprietary medicine of Shri Dhootapapeshwar Ltd. for inducing *Bala* and mitigation of aggravated *Vata Dosha*.

Devadaru (*Cedrus deodara* Roxb), *Daruharidra* (*Barberis aristata*), *Haridra* (*Curcuma longa* Linn), *Vacha* (*Acrois calamus* Linn), *Triphala* (*Embllica officinalis* Gaertn, *Terminalia bellirica* Roxb, *Terminalia chebula* Retz) *Ashwagandha* (*Withania somnifera* Dunal), *Rasna* (*Pluchea lanceolata* Oliver & Hiern) *Churna* was advised for *Lepa* to left lung area, back and lateral aspects for reducing pain and *soshana* (dries up) of accumulated *Ambu*. *Devadaru* mitigates provoked *Vata, Kapha* and is indicated in cough, asthma. *Devadaru* and *Haridra* being *Ushna Veerya* help in *Soshana* of *Ambu* accumulated and are *Shothaghna* (anti-inflammatory). Overall, the management was *Vata* and *Kapha* mitigating targeting the primary *doshas* involved in pathology.

The above treatment protocol was adopted and encouraging outcome was found at each visit of with no adverse effects. Four months and 24 days of follow up and observation demonstrated sustained amelioration of all the symptoms at each visit by around 20 to 30% on ATS Scale (American Thoracic Society) for Dyspnoea and VAS (Visual Analogue Scale) for pain in flank. The line of management adopted was safe alternative to conventional thoracocentesis in this case. Ayurvedic treatment is effective and safe in patients of Pleural effusion matching the above case.

CONCLUSION

The treatment principles of *Udara*, *Shotha*, *Shwasa* and *Kasa* diseases showed efficacy in eliminating the accumulated fluid and simultaneous correction of abnormality in *Dosha*, *Dhatu* and maintaining *Agni* with oral medications has been helped to restore the normalcy of *Pranavaha srotas*. Intersecting the paradigm of conventional pleural effusion treatment, Ayurvedic management exhibited significant effect in the current case with treatment span consisting 32 days of *NV*, 144 days of oral medications that resulted in complete remission. The above discussed case is a fine illustration of how PE with no significant debilitation can be fruitfully managed with Ayurveda.



Fig 1. BEFORE TREATMENT(8/4/2018)

Impression: Left Moderate Pleural Effusion With Underlying Collapse/Consolidation


Fig 2. AFTER TREATMENT(4/8/2018)

Impression: Mild Blunting of Left CP Angle..? Pleural Effusion or Pleural Thickening



Fig 3. Impression: Mild blunting of left CP angle Pleural thickening dated 4/12/2018

REFERENCES:

- The treatment principles of *Udara*, *Shotha*, *Shwasa* and *Kasa* diseases showed efficacy in eliminating the accumulated fluid and simultaneous correction of abnormality in *Dosha*, *Dhatu* and maintaining *Agni* with oral medications has been helped to restore the normalcy of *Pranavaha srotas*. Intersecting the paradigm of conventional pleural effusion treatment, Ayurvedic management exhibited significant effect in the current case with treatment span consisting 32 days of *NV*, 144 days of oral medications that resulted in complete remission. The above discussed case is a fine illustration of how PE with no significant debilitation can be fruitfully managed with Ayurveda.
- 
- Fig 1. BEFORE TREATMENT (8/4/2018)**
Impression: Left Moderate Pleural Effusion With Underlying Collapse/Consolidation
- 
- Fig 2. AFTER TREATMENT (4/8/2018)**
Impression: Mild Blunting of Left CP Angle..? Pleural Effusion or Pleural Thickening
- 
- Fig 3. Impression: Mild blunting of left CP angle Pleural thickening dated 4/12/2018**
- ## REFERENCES:
- Prof. Pal G K. Functional Organization of Respiratory System. In: Textbook of Medical Physiology. 2nd Edition. Ch. 87. New Delhi: Ahuja publishing house; reprint 2013. p.697.
 - Richard W. Light ,Anthony S fauci, Eugene braunwald, dennis, Dennis L.Kasper, Stephen L. Hauser, Dan L. Longo, J.Larry jameson, Joseph Loscalzo ; Harrison's principles of internal medicine: 17th edition :p 1658.
 - Ralston SH, Penman ID, Strachan MWJ, Hobson RP. Respiratory Medicine In: Reid PT, Innes JA , editor. Davidson's Principles and Practice of Medicine. 23rd International edition. Ch.17.New York: ELSEVIER, 2018. p.562
 - Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL , Loscalzo J. Disorders of Pleura and Mediastinum In: Light RW, editor. Harrison's Principles of Internal Medicine. 17th International edition. Ch. 257, Vol. II. New Delhi: Mc Graw Hill, Medical Publishing Division; 2008. p.1659.
 - Shastri AD, commentator. Bhaishajya Ratnavali of Govinda Das Sen, Ch.80.2nd ed. Varanasi: Chaukambha Sanskrit Samsthan;2004. p.806
 - Acharya YT, editor. Susruta Samhitha of Susruta, Chikitsa Sthana, Ch.2, Ver.12-13.8th ed. Varansi: Chaukambha Orientalia; 2005. p. 409.
 - Ibid, Shastri AD. Bhaishajya Ratnavali of Govinda Das Sen. Ch.80.2nd ed. Ver. 6. p. 806
 - Ibid, Shastri AD. Bhaishajya Ratnavali of Govinda Das Sen. Ch.80.2nd ed. Ver.1. p.806
 - Acharya YT, editor. Susruta Samhitha of Susruta, sutrasthana, Ch.35, Ver.49. 8thed. Varanasi: Chauwkambha Orientalia; 2005. p.158.
 - Aptilift, Proprietary product. Manufactured by GMP Certified SANDU Pharmaceuticals Pvt. Ltd. Marra, Bardez, Goa.
 - Acharya YT, editor. Susruta Samhitha of Susruta, Tanta, Ch.42, Ver. 111. 8th ed. Varanasi: Chauwkambha Orientalia; 2005.p.725.
 - Acharya YT, editor. Charaka Samhitha of Agnivesa, Chikitsasthana .Ch.13, Ver. 61. Reprint ed. Varanasi: Chaukambha Orientalia; 2011 edition.p.495.
 - Sitarm Sitarm B, commentator. Bhavaprakasha Nighantu of Bhavamishra, Ch.6, Hareetakyadi Varga, Vol.01, Ver.19. Varanasi: Chaukambha Orientalia. p.132.
 - Dwivedi V, Anandan EM, Mony RS, Muralaeddharan TS, Valiathan MS, Mutsuddi M, et al. (2012) In Vivo Effects Of Traditional Ayurvedic Formulations in Drosophila melanogaster Model Relate with Therapeutic Applications. PLoS ONE 7(5): e37113. <https://doi.org/10.1371/journal.pone.0037113>; Received: November 19, 2011; Accepted: April 13, 2012; Published: May 14, 2012.
 - Bhatia Babita , G K Purushottam. International Journal of Pharmaceutical Sciences Review and Research, Accepted on: 09-07-2013; Finalized on: 31-10-2013. 44(2 47):238-242- June 2017
 - Wenting Wang , Dongxiang Li , Xiaojin Huang , Huixiang Yang , Ziwen Qiu , Liting Zou , Qin Liang , Yu Shi , Yingxiang Wu , Shaohua Wu , Chao Yang , and Yongyu Li. Study on Antibacterial and Quorum-Sensing Inhibition Activities of Cinnamomum camphora Leaf Essential Oil. Received: 24 September 2019; Accepted: 19 October 2019; Published: 21 October 2019. Molecules 2019, 24, 3792; doi:10.3390/molecules24203792.
 - Subramoniam A, Madhavachandran V, Ravi K, Anju VS, Aphordisiac property ofthe elephant creeper Argyrea nervosa, Journal of Endocrinology and Reproduction, 2007; 11:5-19.
 - Philip BK, Muralidharan A, Natarajan B, Varadamurthy S, Venkataraman S. Preliminary evaluation of anti-pyretic and anti-ulcerogenic activities of Sida cordifolia methanolic extract. Fitoterapia 2008; 79: 229-31.
 - K. Radhakrishnan, A. Mohan, Shanmugavadivelu Chandra Mohan and S. Velavan, 2016. A comparison of chemical composition, antioxidant and antimicrobial studies of Abutilon indicum leaves and seeds. Res. J. Phytochem : DOI: 10.3923/rjphyto.2016
 - A Mitra, S Chakraborty, B Auddy, P Tripathi, S Sen, A V Saha, B Mukherjee. evaluation of chemical constituents and free radical scavenging activity of Swarnabhasma (gold ash), an Ayurvedic drug, Journal of Ethnopharmacology,2020;80: 147-153.
 - B K Veena, P.G.Jadar Immunomodulatory Effects of Ayurvedic Drugs: A Review: Volume : 4 | Issue : 11 | November 2014 | ISSN - 2249-555X.
 - Pushkaramruth, Proprietary product. Manufactured by GMP certified Swadeshi Pharmaceuticals Pvt. Ltd, Udupi, Karnataka, India.
 - Ravindra GM, Avinash SD. A review on herbal antiasthmatics. Orient Pharm Exp Med 2011; 11:77–90. Received: 27 January 2011 /Accepted: 1 April 2011 / Published online: 5 July 2011 DOI 10.1007/s13596-011-0019-1.
 - Swamla Compound, Proprietary product. Manufactured by GMP Certified Dhootapapeshwar Pharmaceuticals Pvt. Ltd. Mumbai, India.
 - Shinde UA, Phadke AS, Nair AM, Mungantiwar AA, Dikshit VJ, Saraf MN, Studies on the Anti-inflammatory and Analgesic activity of Cedrus deodara (Roxb.) Loud. Woodoil, vol.65, issue1, 1April 1999. P.21 <https://www.sciencedirect.com/science/article/pii/S0378874198001500?via%3Dihub>